AU2013263763A1 — Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors
Assigned to Concert Pharmaceuticals Inc · Expires 2013-12-19 · 12y expired
What this patent protects
H:\rbr\Interwoven\NRPortbl\DCC\RBR\5836242_I.doc-27/I1/2013 This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel 5 substituted isoindoline-1,3-dione derivativ…
USPTO Abstract
H:\rbr\Interwoven\NRPortbl\DCC\RBR\5836242_I.doc-27/I1/2013 This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel 5 substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.